

The Landscape of Real-world Research of Treatment Patterns and Clinical **Outcomes in Patients Treated with Adalimumab: A Scoping Review** Kiana Imani, PharmD-MBA Candidate^{1*}, Cole Wenner, PharmD-MBA Candidate^{2*}, Catherine M. Lockhart, PharmD, PhD³

BACKGROUND


- Adalimumab is a fully human monoclonal antibody and is a tumor necrosis factor alpha (TNFα) inhibitor indicated for use in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis (PsO), juvenile idiopathic arthritis (JIA), ulcerative colitis (UC), hidradenitis suppurativa (HS), and uveitis (UV)¹
- Since its initial approval in 2002, 10 biosimilars have entered the market but many barriers to patient access still exist ²
- There is a lack of real-world utilization and effectiveness outcomes for adalimumab products

OBJECTIVE

• To develop a comprehensive understanding of observational research and real-world evidence (RWE) evaluating adalimumab use and its biosimilars

METHODS

- Scoping review conducted according to the PRISMA-ScR framework (Figure 1)
- Peer-reviewed articles published in English anytime up to July 4th, 2023, were included
- Included studies were observational (prospective or retrospective), conducted in the United States, and included patients aged 18 years or older treated with adalimumab for any approved or off-label indication
- Data were descriptively analyzed and summarized based on overall trends, similarities, and differences across included studies and stratified by disease state



¹University of Washington, Seattle, WA; ²Wilkes University, Wilkes-Barre, PA; ³Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, VA

	Citation	Article Title	Outcome measures	Fin
RESULTS	Bagel J, et al. <i>J Med</i> <i>Econ.</i> 2021;24(1):782- 791	Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data	Above-label use, dose escalation, duration of above- label use, and associated costs.	Of 4,141 patients receiving adalimumab, 513 use was 99.5 days. Median duration of abov use resulted in \$50,569 and above label use
Figure 2: Studies' Data Sources	Blume SW, et al. <i>Adv</i> <i>Ther.</i> 2013;30(5):517- 527	Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting	Duration, persistence, and dose escalation rates.	Of 852 patients on adalimumab; 45.9% were significantly higher rates of dose escalation t escalation rates were 8.3–14.1%. For continu
	Delate T, et al. <i>J Manag</i> <i>Care Spec Pharm.</i> 2017;23(8):798-808.	Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis	Prevalence of low-dose and high-dose outliers by index biologic.	ADA patients were most likely to become out patients were more likely to be a high-dose of Total biologic costs were highest for ADA and
	Doshi JA, et al. <i>J Am</i> <i>Acad Dermatol.</i> 2016;74(6):1057-1065.	Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population	Adherence, discontinuation, switching, and restarting of the index biologic.	We examined 1,083 patients initiating adalim discontinued, 9.0% switched, 6.6% restarted
	Feldman SR, et al. <i>J</i> <i>Manag Care Spec</i> <i>Pharm.</i> 2015;21(3):201- 209.	Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis	Dose escalation, switching, restarting, or discontinuation.	Of the 1,681 patients on adalimumab 37% exmonths, 10% restarted the same biologic, an persistence rate over 12 months was 53%.
	Feldman SR, et al. <i>J</i> <i>Dermatolog Treat.</i> 2021;32(2):203-211.	Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status	Adherence, non-persistence, discontinuation, re-initiation, switching, combination therapy, and total costs.	Patients with metabolic conditions had highe adalimumab; 53.9% vs. 48.7% and 47.8% vs conditions incurred significantly higher costs
	Harrold LR, et al. <i>J</i> <i>Rheumatol.</i> 2020;47(7):959-967.	Long-term, real-world safety of adalimumab in rheumatoid arthritis	Serious infections, malignancies, CHF requiring hospitalization, TB, drug- induced SLE, and mortality.	Incidence per 100 person-years for serious in and mortality were 1.86, 0.15, 0.64, and 0.33 highest in the first year of therapy. The median the median time to first serious infection was
Claims Data (n = 6, 54.5%) Registries (n = 2, 18.2%) Encounters Database (n = 2, 18.2%) Supplemental Database (n = 1, 9.1%) Pharmacy Benefits Manager (n = 1, 9.1%) * One study utilized both claims and encounters data and is accounted for twice in Figure 2.	Khilfeh I, et al. <i>J Manag</i> <i>Care Spec Pharm.</i> 2019;25(4):461-467.	Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study	Adherence, persistence, switch rates, and direct medical costs	ADA (n = 226) was the second most used m with higher persistence (+307 days with ADA ADA was abatacept (n = 39).
	Edward V., et al. <i>Journal</i> <i>of Crohn's and Colitis.</i> 2011; 5(6): 550–554	Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States	Mean of age, duration of follow up, sex, dose, region.	1,335 patients received ADA as maintenance years and duration of follow up was 253 (±17 adalimumab 160/80 mg as induction therapy
	Pappas DA, et al. <i>Rheumatol Ther.</i> 2017;4(2):375-389.	Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry	Patient demographics, clinical characteristics, persistency, disease activity, functionality	Of the 1,791 ADA new starts, persistence of respectively. 67% of those persisting at least were in remission with clinically meaningful i were not in remission and 41.9% switched b
inclusion criteria, the average sample size was 2,091 patients.	Xu C, et al. <i>J</i> <i>Dermatolog Treat.</i> 2022;33(4):2270-2277.	Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population	Adherence and persistence	During the 9-month follow-up period, the pro The proportion of patients who were persiste month follow-up period was 30.7%.
REFERENCES		CONCLUSIONS		
 Ellis CR, Azmat CE. Adalimumab. [Updated 2023 Nov 12]. In: StatPear 	ls [Internet]. Treasure		wities we get DN/C studies are desi	gned retrospectively and are used to assess

ACKNOWLEDGEMENTS

This study was funded by the Biologics and Biosimilars Collective Intelligence Consortium.

ess adherence, persistence, discontinuation,

label, increasing the risk of infections, and first e past 12 months was around 50% Majority of studies are funded by pharmaceutical manufacturers

These findings will help identify potential gaps in literature which can inform future studies

* These authors contributed equally

indings

13 were above label. Mean time to above label oove label use was just below 150 days. Labeled use resulted in \$61,102 all cause costs.

ere new starts. Patients receiving ADA had on than those receiving ETA. New starts dose tinuing patients, rates ranged from 7.0–28.3%.

outliers. Of all outliers during the 1-year follow-up, e outlier (55%) than a low-dose outlier (45%). and ETA nonoutliers.

alimumab. 40.7% were adherent, 43.4% ted (5.1% with index, 1.5% with different biologic).

escalated doses, 27% discontinued within 12 and 10% switched to another biologic. The

ther discontinuation and switching rates while on vs. 41.9%, respectively. Patients with metabolic

s infections, CHF hospitalizations, malignancies, .33, respectively. The risk of serious infection was edian time to discontinuation was 11 months, while as 12 months

I medication. Concurrent MTX use was associated DA). The most commonly switched-to drug after

nce therapy. Mean age of the sample was 41 (±14) ±111) days. 58% were women, 85% had received apy, and 55% were from Southern USA.

of at least 1 and 12 years was 64.1% and 10.2%, ast 1 year (77.1% female, mean age 53.9 years) ul improvements. 61.6% of those who discontinued I biologic within 12 months after discontinuing

proportion of patients with PDC 80% was 48.6%. stent with their index biologic (ADA) during the 9-